mRNA vaccine technology has gained considerable attention since the first vaccines were produced in response to the COVID-19 pandemic. This technology is now being expanded to develop a wide range of vaccines against a suite of common diseases. The Noxopharm Sofra™ technology platform is targeting improvements in mRNA technologies.
One of the challenges encountered by current vaccine manufacturers how to create an effective and long-lasting vaccine while minimising inflammatory side effects such as headache, fatigue and muscle pain.
These side-effects occur due to the activation of inflammation receptors in the body known as toll-like receptor 7, or TLR 7.
When an mRNA vaccine is given, the mRNA gives the body signals to develop an immune response to the target virus e.g. COVID-19. Some of this mRNA also breaks down into fragments that bind to TLR7 inflammation receptors, switching on an inflammatory response that can result in undesired side-effects.
SOF-VAC™ is an oligonucleotide (short nucleic acid sequences, the building blocks of DNA or RNA) in preclinical development. It is designed to block TLR 7 receptors and reduce vaccine related inflammation at its source.
Download the SOF-VAC Fact Sheet pdf here